Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer

Nina Rehfeld, Helene Geddert, Abedelsalam Atamna, Helmut E. Gabbert, Ulrich G. Steidl, Roland Fenk, Ralf Kronenwett, Rainer Haas, Ulrich Peter Rohr

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: In a retrospective analysis of 195 patients with small cell lung cancer (SCLC), we examined the prognostic value of a coexpression of fragile histidine triad (FHIT) protein and c-kit on patient's survival. Methods: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 195 patients with SCLC were evaluated for FHIT and c-kit coexpression. Results: Coexpression of FHIT and c-kit was observed in 53.3%; a positive expression of either FHIT or c-kit was found in 40.5%. Complete lack of FHIT and c-kit (6.2%) was associated with a significantly shorter survival time for the patients with a mean of 122 ± 45 days compared with 468 ± 89 days for patients with lung cancer coexpressing FHIT and c-kit (P = 0.0011). The proportion of FHIT- and c-kit-positive cells within a tumor was also related to survival time. Patients with tumors with a proportion between 0% to 25% of FHIT-and c-kit-positive cells had the worst survival of 157 ± 34 days compared with 496 ± 95 days for patients showing >25% FHIT- and c-kit-positive cells (P = 0.0002). Further, variables associated with shorter survival times were low performance status, elevated lactate dehydrogenase level, and advanced tumor stage according to tumor-node-metastasis classification. Multivariate analysis using Cox regression model, including 11 variables, confirmed the prognostic significance of a combined expression of FHIT and c-kit next to tumor stage, performance status, and lactate dehydrogenase level. Conclusions: Differential FHIT and c-kit expression was of prognostic relevance for survival in patients with SCLC and therefore provide useful variables for therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)2232-2238
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Histidine
Survival
Neoplasms
L-Lactate Dehydrogenase
Proportional Hazards Models
Paraffin
Formaldehyde
Lung Neoplasms
Multivariate Analysis
Immunohistochemistry
Neoplasm Metastasis

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer. / Rehfeld, Nina; Geddert, Helene; Atamna, Abedelsalam; Gabbert, Helmut E.; Steidl, Ulrich G.; Fenk, Roland; Kronenwett, Ralf; Haas, Rainer; Rohr, Ulrich Peter.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 11, 11.2006, p. 2232-2238.

Research output: Contribution to journalArticle

Rehfeld, Nina ; Geddert, Helene ; Atamna, Abedelsalam ; Gabbert, Helmut E. ; Steidl, Ulrich G. ; Fenk, Roland ; Kronenwett, Ralf ; Haas, Rainer ; Rohr, Ulrich Peter. / Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 11. pp. 2232-2238.
@article{afc6c46220e34d92a64ac5f58db22c2b,
title = "Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer",
abstract = "Background: In a retrospective analysis of 195 patients with small cell lung cancer (SCLC), we examined the prognostic value of a coexpression of fragile histidine triad (FHIT) protein and c-kit on patient's survival. Methods: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 195 patients with SCLC were evaluated for FHIT and c-kit coexpression. Results: Coexpression of FHIT and c-kit was observed in 53.3{\%}; a positive expression of either FHIT or c-kit was found in 40.5{\%}. Complete lack of FHIT and c-kit (6.2{\%}) was associated with a significantly shorter survival time for the patients with a mean of 122 ± 45 days compared with 468 ± 89 days for patients with lung cancer coexpressing FHIT and c-kit (P = 0.0011). The proportion of FHIT- and c-kit-positive cells within a tumor was also related to survival time. Patients with tumors with a proportion between 0{\%} to 25{\%} of FHIT-and c-kit-positive cells had the worst survival of 157 ± 34 days compared with 496 ± 95 days for patients showing >25{\%} FHIT- and c-kit-positive cells (P = 0.0002). Further, variables associated with shorter survival times were low performance status, elevated lactate dehydrogenase level, and advanced tumor stage according to tumor-node-metastasis classification. Multivariate analysis using Cox regression model, including 11 variables, confirmed the prognostic significance of a combined expression of FHIT and c-kit next to tumor stage, performance status, and lactate dehydrogenase level. Conclusions: Differential FHIT and c-kit expression was of prognostic relevance for survival in patients with SCLC and therefore provide useful variables for therapeutic decisions.",
author = "Nina Rehfeld and Helene Geddert and Abedelsalam Atamna and Gabbert, {Helmut E.} and Steidl, {Ulrich G.} and Roland Fenk and Ralf Kronenwett and Rainer Haas and Rohr, {Ulrich Peter}",
year = "2006",
month = "11",
doi = "10.1158/1055-9965.EPI-06-0342",
language = "English (US)",
volume = "15",
pages = "2232--2238",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer

AU - Rehfeld, Nina

AU - Geddert, Helene

AU - Atamna, Abedelsalam

AU - Gabbert, Helmut E.

AU - Steidl, Ulrich G.

AU - Fenk, Roland

AU - Kronenwett, Ralf

AU - Haas, Rainer

AU - Rohr, Ulrich Peter

PY - 2006/11

Y1 - 2006/11

N2 - Background: In a retrospective analysis of 195 patients with small cell lung cancer (SCLC), we examined the prognostic value of a coexpression of fragile histidine triad (FHIT) protein and c-kit on patient's survival. Methods: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 195 patients with SCLC were evaluated for FHIT and c-kit coexpression. Results: Coexpression of FHIT and c-kit was observed in 53.3%; a positive expression of either FHIT or c-kit was found in 40.5%. Complete lack of FHIT and c-kit (6.2%) was associated with a significantly shorter survival time for the patients with a mean of 122 ± 45 days compared with 468 ± 89 days for patients with lung cancer coexpressing FHIT and c-kit (P = 0.0011). The proportion of FHIT- and c-kit-positive cells within a tumor was also related to survival time. Patients with tumors with a proportion between 0% to 25% of FHIT-and c-kit-positive cells had the worst survival of 157 ± 34 days compared with 496 ± 95 days for patients showing >25% FHIT- and c-kit-positive cells (P = 0.0002). Further, variables associated with shorter survival times were low performance status, elevated lactate dehydrogenase level, and advanced tumor stage according to tumor-node-metastasis classification. Multivariate analysis using Cox regression model, including 11 variables, confirmed the prognostic significance of a combined expression of FHIT and c-kit next to tumor stage, performance status, and lactate dehydrogenase level. Conclusions: Differential FHIT and c-kit expression was of prognostic relevance for survival in patients with SCLC and therefore provide useful variables for therapeutic decisions.

AB - Background: In a retrospective analysis of 195 patients with small cell lung cancer (SCLC), we examined the prognostic value of a coexpression of fragile histidine triad (FHIT) protein and c-kit on patient's survival. Methods: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 195 patients with SCLC were evaluated for FHIT and c-kit coexpression. Results: Coexpression of FHIT and c-kit was observed in 53.3%; a positive expression of either FHIT or c-kit was found in 40.5%. Complete lack of FHIT and c-kit (6.2%) was associated with a significantly shorter survival time for the patients with a mean of 122 ± 45 days compared with 468 ± 89 days for patients with lung cancer coexpressing FHIT and c-kit (P = 0.0011). The proportion of FHIT- and c-kit-positive cells within a tumor was also related to survival time. Patients with tumors with a proportion between 0% to 25% of FHIT-and c-kit-positive cells had the worst survival of 157 ± 34 days compared with 496 ± 95 days for patients showing >25% FHIT- and c-kit-positive cells (P = 0.0002). Further, variables associated with shorter survival times were low performance status, elevated lactate dehydrogenase level, and advanced tumor stage according to tumor-node-metastasis classification. Multivariate analysis using Cox regression model, including 11 variables, confirmed the prognostic significance of a combined expression of FHIT and c-kit next to tumor stage, performance status, and lactate dehydrogenase level. Conclusions: Differential FHIT and c-kit expression was of prognostic relevance for survival in patients with SCLC and therefore provide useful variables for therapeutic decisions.

UR - http://www.scopus.com/inward/record.url?scp=33845284534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845284534&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0342

DO - 10.1158/1055-9965.EPI-06-0342

M3 - Article

VL - 15

SP - 2232

EP - 2238

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -